Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ceapro Inc (OP: CRPOF ) N/A UNCHANGED Last Price Updated: 11:58 AM EDT, May 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.1700 Today's Range N/A - N/A 52wk Range 0.1146 - 0.2890 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Aeterna Zentaris and Ceapro Complete Merger Transaction June 03, 2024 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update May 29, 2024 From Ceapro Inc. Via GlobeNewswire Performance More News Read More Ceapro Inc. Reports 2023 Financial Results and Operational Highlights April 29, 2024 From Ceapro Inc. Via GlobeNewswire Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris March 28, 2024 From Ceapro Inc. Via GlobeNewswire Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings March 12, 2024 From Ceapro Inc.; Aeterna Zentaris Inc. Via GlobeNewswire Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company February 26, 2024 From Ceapro Inc. Via GlobeNewswire Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business February 23, 2024 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris February 15, 2024 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases December 13, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights November 29, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases November 27, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology November 07, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update August 29, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise August 25, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation July 18, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro to Participate in the Virtual Investor Summer Spotlight Series July 05, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Announces Results of 2023 Shareholders’ Meeting June 07, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update May 25, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases May 23, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration May 03, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations April 27, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights April 12, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference March 23, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society March 08, 2023 From Ceapro Inc. Via GlobeNewswire Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company February 21, 2023 From Ceapro Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.